Table 2 Patient characteristics and perioperative data
|  | Reoperation n = 48 | No reoperation n = 385 | P |
|---|---|---|---|
Gender, m:f (ratio) | 27:21 (1.28) | 217:168 (1.29) | 0.88 |
Age (years) | 66.5 ± 11.4 | 64.6 ± 11.9 | 0.3 |
Comorbidities: | |||
 HTN, n (%) | 14 (29.1) | 97 (25.1) | 0.57 |
 IHD, n (%) | 5 (10.4) | 37 (9.6) | 0.64 |
 DM, n (%) | 9 (18.7) | 118 (30.6) | 0.19 |
 COPD, n (%) | 1 (2) | 2 (0.5) | < 0.001 |
 Pre-op Hb | 12.64 ± 1.5 | 12.27 ± 1.6 | 0.18 |
 CEA | 3.73 ± 6.0 | 5.52 ± 14.8 | 0.54 |
 CA19-9 | 174 ± 289 | 209 ± 309 | 0.57 |
 Pre-op bilirubin | 7.3 ± 6 | 4.19 ± 5.4 | 0.048 |
 Pre-op GGT | 523 ± 497 | 458 ± 559 | 0.53 |
 Neo-adjuvant Tx, n (%) | 2 (4.1) | 12 (3.11) | 0.14 |
 Benign pathology, n (%) | 2 (4.1) | 31 (8) | 0.13 |
 Malignant pathology, n (%) | 46 (95.9) | 354 (91.9) | 0.013 |
 PDAC, n (%) | 28 (58.3) | 198 (51.4) | 0.98 |
 Ampullary CA, n (%) | 6 (12.5) | 47 (12.2) | 0.814 |
 Duodenal CA, n (%) | 1 (2) | 15 (3.8) | 0.014 |
 CCA, n (%) | 5 (10.4) | 15 (3.9) | < 0.001 |
 ERCP + stenting (all malignant), n (%) | 18 (39.1) | 92 (25.9) | 0.259 |
 ERCP + stenting (of CA, not CCA), n (%) | 12 (34.2) | 67 (25.5) | 0.57 |
 ERCP + stenting (of CCA), n (%) | 2 (40) | 11 (73.3) | 0.15 |
Staging of CA patients | |||
 T1, n (%) | 11 (27.5) | 90 (32.4) | 0.816 |
 T2, n (%) | 13 (32.5) | 108 (38.9) | 0.85 |
 T3, n (%) | 6 (15) | 31 (11.2) | 0.23 |
 T4, n (%) | 10 (25) | 48 (17.4) | 0.2 |
 At least one positive LN, n (%) | 20 (50) | 140 (50.9) | 0.87 |
 No. of positive LN, average (range) | 2.3 (1–7) | 3.2 (1–21) | 0.19 |
 NET, n (%) | 2 (4.16) | 31 (8) | 0.01 |
 IPMN, n (%) | 1 (2) | 40 (10.3) | < 0.001 |
 Readmission, n (%) | 11 (22.9) | 66 (17.1) | 0.24 |
 DGE, n (%) | 3 (6.2) | 57 (14.8) | 0.002 |
 Wound infection, n (%) | 4 (8.3) | 63 (16.3) | 0.019 |
 B/C pancreatic fistula, n (%) | 7 (14.5) | 57 (14.8) | 0.93 |
 Tracheostomy, n (%) | 7 (14.5) | 2 (0.52) | < 0.001 |
 LOS (days), average (range) | 39.07 ± 30.15 | 16.5 ± 10.3 | < 0.001 |
 60 days’ mortality, n (%) | 9 (18.75) | 10 (2.6) | < 0.001 |
 Adjuvant Tx, n (% of CA patients) | 23 (57.5) | 181 (65.8) | 0.58 |